RENNOVA HEALTH, INC. (NASDAQ:RNVA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
As previously announced, on September 19, 2017 Rennova Health, Inc. (the “Company”) closed offerings of an aggregate of $9,016,136 principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 (the “Debentures”) and Warrants to purchase shares of the Company’s common stock. to the terms of a Second Amendment, dated as of October 19, 2017 (the “Amendment”), the Company and the purchasers of the Debentures amended the amortization terms of the Debentures so that the Debentures would begin to amortize immediately. Amortization can directly affect the dilution adjustment of warrants issued by the Company as fully described in our recently effective registration statement on Form S-1, File No. 219145. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety be reference to the full text of the Amendment, which is filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.
Item 3.03 Material Modification to Rights of Security Holders.
The information set forth in Item 1.01 is incorporated herein by reference.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. |
On October 13, 2017, Michael Pollack resigned as Interim Chief Financial Officer of the Company. In submitting his resignation, Mr. Pollack did not express any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company is currently seeking a full-time Chief Financial Officer.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Rennova Health, Inc. ExhibitEX-10.159 2 ex10-159.htm SECOND AMENDMENT Second Amendment,…To view the full exhibit click here
About RENNOVA HEALTH, INC. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.
